ProfileGDS5678 / 1420619_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 92% 92% 92% 93% 91% 90% 91% 91% 91% 91% 92% 92% 92% 92% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.5219892
GSM967853U87-EV human glioblastoma xenograft - Control 27.6915692
GSM967854U87-EV human glioblastoma xenograft - Control 37.6397592
GSM967855U87-EV human glioblastoma xenograft - Control 47.9788993
GSM967856U87-EV human glioblastoma xenograft - Control 57.5597391
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.9522590
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.2481691
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.4189591
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.4275791
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.4710691
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.4988392
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.6186692
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.5953792
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.5382192